Tempus AI, Inc. $TEM Stake Cut by Renaissance Capital LLC

Key Points

• Renaissance Capital trimmed its stake by 27.9% in Tempus AI in Q4, selling 23,479 shares and leaving the fund with 60,687 shares valued at $3.584 million (about 2.6% of the fund and its 15th largest holding).
• Significant insider selling occurred recently: CEO Ryan Fukushima and EVP Andrew Polovin sold shares, and insiders disposed of 563,841 shares worth $32.26 million in the last quarter, although insiders still own roughly 24.26% of the company.
• Positive catalysts and mixed analyst views: Tempus announced a strategic collaboration with USC and is showing improving fundamentals (rising gross profit and positive EBITDA), contributing to a consensus "Moderate Buy" with a $71.36 target amid continued stock volatility.

Renaissance Capital LLC trimmed its stake in Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 27.9% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 60,687 shares of the company's stock after selling 23,479 shares during the quarter. Tempus AI makes up about 2.6% of Renaissance Capital LLC's investment portfolio, making the stock its 15th largest holding. Renaissance Capital LLC's holdings in Tempus AI were worth $3,584,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. JPL Wealth Management LLC bought a new stake in Tempus AI in the third quarter valued at $26,000. GAMMA Investing LLC bought a new stake in Tempus AI in the third quarter valued at $28,000. Harvest Fund Management Co. Ltd bought a new stake in Tempus AI in the third quarter valued at $38,000. Lodestone Wealth Management LLC bought a new stake in Tempus AI in the fourth quarter valued at $42,000. Finally, Tsfg LLC lifted its stake in Tempus AI by 1,515.2% in the third quarter. Tsfg LLC now owns 533 shares of the company's stock valued at $43,000 after buying an additional 500 shares during the last quarter. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Price Performance

Shares of Tempus AI stock opened at $52.12 on Monday. The company has a current ratio of 3.13, a quick ratio of 3.00 and a debt-to-equity ratio of 2.52. The company's 50-day moving average price is $50.87 and its two-hundred day moving average price is $64.38. Tempus AI, Inc. has a 52 week low of $41.73 and a 52 week high of $104.32. The stock has a market cap of $9.32 billion, a PE ratio of -36.96 and a beta of 4.90.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus announced a multi-faceted strategic collaboration with the Keck School of Medicine of USC and Keck Medicine of USC to apply AI to precision medicine across a large patient base — a partnership that supports commercial adoption and revenue opportunity. Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine
• Positive Sentiment: Analyst/coverage note: Zacks highlights that Tempus is nearing profitability as gross profit rises and EBITDA turns positive — a material fundamental improvement that could support valuation re-rating if GAAP losses continue to narrow. Tempus AI Nears Profitability as Operating Leverage Emerges
• Positive Sentiment: Investor interest: coverage noted that ARK/Cathie Wood is adding next‑gen tech positions that include Tempus — institutional demand from growth-focused funds can amplify positive momentum. Cathie Wood Is Loading Up on These 3 Next‑Gen Tech Stocks
• Neutral Sentiment: Market commentary: broader write-ups suggest TEM has been choppy — short‑term declines but still mixed returns over 1 month and 1 year — signaling investor debate over growth vs. near-term profitability. Is It Time To Reassess Tempus AI (TEM) After Recent Share Price Volatility?
• Neutral Sentiment: Short interest report shows effectively zero reported short interest and a 0.0 days‑to‑cover figure (data appears anomalous), which implies no meaningful short squeeze pressure but also suggests data noise — watch for clarified filings.
• Negative Sentiment: Despite the USC partnership, some market coverage flagged a rapid intraday sell‑off (reported ~7% drop in one note), underscoring how news-flow and headline trading can produce short-term downside even amid positive fundamentals. Tempus AI (TEM) Stock Drops 7% Despite Landmark USC Medical Partnership

Insider Transactions at Tempus AI

In other Tempus AI news, CEO Ryan Fukushima sold 9,592 shares of the business's stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $566,407.60. Following the sale, the chief executive officer directly owned 694,354 shares in the company, valued at approximately $41,001,603.70. The trade was a 1.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Andrew Polovin sold 10,949 shares of the business's stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $60.31, for a total transaction of $660,334.19. Following the completion of the sale, the executive vice president owned 126,918 shares in the company, valued at approximately $7,654,424.58. This trade represents a 7.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 563,841 shares of company stock valued at $32,258,311 in the last quarter. 24.26% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on TEM shares. HC Wainwright raised their target price on Tempus AI from $89.00 to $95.00 and gave the company a "buy" rating in a research note on Monday, March 9th. BTIG Research cut their target price on Tempus AI from $105.00 to $90.00 and set a "buy" rating on the stock in a research note on Wednesday, February 25th. Stifel Nicolaus set a $60.00 target price on Tempus AI in a research note on Wednesday, February 25th. JPMorgan Chase & Co. cut their target price on Tempus AI from $80.00 to $60.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 25th. Finally, TD Cowen upgraded Tempus AI from a "hold" rating to a "buy" rating and set a $65.00 target price on the stock in a research note on Monday, April 13th. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $71.36.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.